KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Interest & Investment Income (2020 - 2025)

Aurinia Pharmaceuticals' Interest & Investment Income history spans 6 years, with the latest figure at $3.5 million for Q4 2025.

  • For Q4 2025, Interest & Investment Income fell 12.29% year-over-year to $3.5 million; the TTM value through Dec 2025 reached $13.6 million, down 20.02%, while the annual FY2025 figure was $13.6 million, 20.02% down from the prior year.
  • Interest & Investment Income reached $3.5 million in Q4 2025 per AUPH's latest filing, up from $3.3 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $4.6 million in Q4 2023 to a low of $106000.0 in Q3 2021.
  • Average Interest & Investment Income over 5 years is $2.7 million, with a median of $3.4 million recorded in 2025.
  • Peak YoY movement for Interest & Investment Income: tumbled 80.67% in 2021, then skyrocketed 2568.81% in 2022.
  • A 5-year view of Interest & Investment Income shows it stood at $109000.0 in 2021, then surged by 2568.81% to $2.9 million in 2022, then skyrocketed by 57.03% to $4.6 million in 2023, then decreased by 12.7% to $4.0 million in 2024, then decreased by 12.29% to $3.5 million in 2025.
  • Per Business Quant, the three most recent readings for AUPH's Interest & Investment Income are $3.5 million (Q4 2025), $3.3 million (Q3 2025), and $3.2 million (Q2 2025).